In vitro and in vivo efficacy of α-cyclodextrin for treatment of experimental cryptosporidiosis

Veterinary Parasitology

Volumn 114, Issue 4, 2003, Pages 237-245

  Castro Hermida, Jose A ^a   Ares Mazas M E ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Control methods protozoa; Cryptosporidium parvum; In vitro viability; In vivo infectivity; Cyclodextrin

Indexed keywords

ALPHA CYCLODEXTRIN; GLUCOSE; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; INTESTINE; MOUSE; NEWBORN; NONHUMAN; OOCYST; TECHNIQUE; TISSUE HOMOGENATE; VITAL STAIN;

ANIMALIA; CRYPTOSPORIDIUM; CRYPTOSPORIDIUM PARVUM; PROTOZOA;

EID: 0038180894     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4017(03)00156-0     Document Type: Article

References (24)

1. Buschmann H.J., Schollmeyer E. Applications of cyclodextrins in cosmetic products: a review. J. Cosmet. Sci. 53:2002;185-191.
2. Campbell A.T., Robertson L.J., Smith H.V. Viability of Cryptosporidium parvum oocysts: correlation of in vitro excystation with inclusion or exclusion of fluorogenic vital dyes. Appl. Environ. Microbiol. 58:1992;3488-3493.
3. Castro-Hermida J.A., Freire-Santos F., Oteiza-Lopez A.M., Ares-Mazás E. Unexpected activity of β-cyclodextrin against experimental infection by Cryptosporidium parvum. J. Parasitol. 86:2000;1118-1120.
4. Castro-Hermida J.A., González-Losada Y., Freire-Santos F., Mezo-Menéndez M., Ares-Mazás E. Evaluation of β-cyclodextrin against natural infections of cryptosporidiosis in calves. Vet. Parasitol. 101:2001;85-89.
5. Castro-Hermida J.A., Quilez-Cinca J., Lopez-Bernad F., Sanchez-Acedo C., Freire-Santos F., Ares-Mazás E. Treatment with β-cyclodextrin of natural Cryptosporidium parvum infections in lambs under field conditions. Int. J. Parasitol. 31:2001;1134-1137.
6. Coombs G.H., Müller S. Recent advances in the search for new anti-coccidial drugs. Int. J. Parasitol. 32:2002;497-508.
7. Current W.L., Garcia L.S. Cryptosporidiosis. Clin. Microbiol. Rev. 4:1991;325-358.
8. Fayer R., Trout J.M., Xiao L., Morgan U.M., Lal A.A., Dubey J.P. Cryptosporidium canis n sp. from domestic dogs. J. Parasitol. 87:2001;1415-1422.
9. Gilles H.M., Hoffman P.S. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. 18:2002;95-97.
10. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:1997;147-162.
11. Irie T., Uekama K. Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 36:1999;101-123.
12. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85:1996;1017-1025.
13. Lorenzo M.J., Ares-Mazás M.E., Villacorta I., Duran D. Effect of ultraviolet disinfection of drinking water on the viability of Cryptosporidium parvum oocysts. J. Parasitol. 79:1993;67-70.
14. Mitschler R.R., Welti R., Upton S.J. A comparative study of lipid compositions of Cryptosporidium parvum (Apicomplexa) and Madin-Darby bovine kidney cells. J. Eukaryot. Microbiol. 41:1994;8-12.
15. Monti S., Sortino S. Photoprocesses of photosensitizing drugs within cyclodextrin cavities. Chem. Soc. Rev. 31:2002;287-300.
16. Morgan U.M., Xiao L., Fayer R., Lal A.A., Thompson R.C.A. Variation in Cryptosporidium towards a taxonomic revision of the genus. Int. J. Parasitol. 29:1999;1733-1751.
17. Ohtani Y., Irie T., Uekama K., Fukunaga K., Pitha J. Differential effects of α-3- and β-cyclodextrins on human erythrocytes. Eur. J. Biochem. 186:1989;17-22.
18. Pedraza-Diaz S., Amar C., Iversen A.M., Stanley P.J., McLauchlin J. Unusual Cryptosporidium species recovered from human faeces: first description of Cryptosporidium felis and Cryptosporidium dog type from patients in England. J. Med. Microbiol. 50:2001;293-296.
19. Pitha J., Irie T., Skalar P.B., Nye J.S. Drugs solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci. 43:1988;493-502.
20. Rajewski R.A., Stella V.J. Pharmaceutical application of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85:1996;1142-1169.
21. Redenti E., Piedra C., Gerlocy A., Szente L. Cyclodextrins in oligonucleotide delivery. Adv. Drug Deliv. Rev. 53:2001;235-244.
22. Vergara Castiblanco, C.A., 1999. Estudio inmunologico de la cryptosporidiosis humana en Colombia. Thesis. Universidad de Santiago de Compostela, Spain.
23. Xiao L., Morgan U.M., Fayer R., Thompson R.C.A., Lal A.A. Cryptosporidium systematics and implications for public health. Parasitol. Today. 26:2000;287-292.
24. Yagita K., Izumiyama S., Tachibana H., Masuda G., Iseki M., Furuya K., Kameoka Y., Kuroki T., Itagaki T., Endo T. Molecular characterization of Cryptosporidium isolates obtained from human and bovine infections in Japan. Parasitol. Res. 87:2001;950-955.